October 2017

Oral Oncolytic Agents: New Caregiver Challenges

January 24, 2018

Partner Perspectives

The use of oral oncolytic agents is on the rise, and these medications now account for a large percentage of all prescribed cancer treatments. Although oral agents offer a convenient alternative to traditional intravenous (IV) chemotherapy, they present new and unique challenges to caregivers.

Angiogenesis Inhibitor Tested in Mesothelioma Trial

October 11, 2017

Clinical Trials in Progress

Although it is estimated that malignant mesothelioma represents less than 1% of all cancers, it is a fatal asbestos-associated malignancy, and patients with MPM tend to be difficult to treat.

Staying on Course: Nurses Have the Power Over Oral Adherence

October 04, 2017

From the Chairman

Discoveries are made every day in the treatment of cancer. Fortunately, many are now in the form of oral drugs, which offer convenience to patients, who can take them from the comfort of their home instead of having to travel to a cancer center. But that easy accessibility comes with a cost: nonadherence.